Need professional-grade analysis? Visit stockanalysis.com
$12.67B
N/A
185
N/A
InventisBio Co. Ltd. A (688382) trades on SHG in CNY. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at CNY22.07, down 2.47% from the previous close.
Over the past year, 688382 has traded between a low of CNY17.35 and a high of CNY47.90. The stock has lost 2.5% over this period. It is currently 53.9% below its 52-week high.
InventisBio Co. Ltd. A has a market capitalization of $12.67B.
InventisBio Co., Limited, a clinical stage biotech company, engages in the discovery and development of therapeutics for cancer and metabolic diseases in China. The company's drug candidates for the oncology therapeutic area include BPI-D0316, which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; Taragarestrant, which is in Phase III clinical trial for the treatment of estrogen receptor positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer; and Gesorexel, which in Phase II clinical trial to treat various cancers, such as non-small cell lung cancer and colorectal cancer with KRASG12C mutations. Its drug candidates for the metabolic therapeutic area is D-0120, a Phase II clinical trial product for hyperuricemia and gout indications; and D-2570, a oral selective inhibitor for the treatment of autoimmune diseases such as psoriasis. In addition, the company offers preclinical products, including YF 087 for MSI high cancers, and YF550 for chromosome instability cancers. InventisBio Co., Limited was founded in 2013 and is headquartered in Pudong, China.
Side-by-side comparison against top Healthcare peers.